GSK plc (GLAXF)
| Market Cap | 76.98B |
| Revenue (ttm) | 39.74B |
| Net Income (ttm) | 5.10B |
| Shares Out | n/a |
| EPS (ttm) | 1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.38 (1.99%) |
| Ex-Dividend Date | Aug 15, 2024 |
| Volume | 164 |
| Open | 18.77 |
| Previous Close | 19.23 |
| Day's Range | 18.77 - 18.77 |
| 52-Week Range | 16.80 - 23.00 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2024 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]
Financial Performance
In 2023, GSK plc's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.
Financial numbers in GBP Financial StatementsNews
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for...
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK stays in red for seven straight sessions
Haleon: Too Vanilla For My Liking - I See Why GSK & Pfizer Wanted Out
Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock and why I recommend a sell rating.
GSK reports positive data for RSV shot in younger, at-risk adults
Companies Reporting: McDonalds, Aston Martin, GSK, Next
McDonalds, Aston Martin, GSK, Next are amongst the FTSE 350 and other companies reporting earnings for the week of 28 November
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines fo...
New Data for AREXVY, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--New data for AREXVY, GSK's RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.
Moderna: Assessing The Impact Of GSK's Patent Lawsuit
GSK's lawsuit adds uncertainty to Moderna's already declining stock, increasing short-selling activity. Read why I downgrade MRNA from buy to hold.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Investigating Eli Lilly's Standing In Pharmaceuticals Industry Compared To Competitors
In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehe...
ViiV reports positive real-world data for HIV prevention drug
ViiV Healthcare, which is co-owned by GSK (GSK) and Pfizer (PFE), said real-world studies showed its drug Apretude was more than 99% effective as a preventive treatment for HIV.
GSK antibiotic for UTI accepted for FDA priority review
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
GSK Plc (NYSE: GSK) has filed a lawsuit against Moderna, Inc. (NASDAQ: MRNA) and its affiliates, alleging that Moderna’s mRNA vaccines infringe on patents developed by GSK . According to GSK, the te...
Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R
Last week, Sanofi SA (NASDAQ: SNY) said it is negotiating with Clayton Dubilier & Rice (CD&R) to potentially sell a 50% controlling stake in Opella, its consumer healthcare business . The deal could ...
GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines
GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.
GSK reports positive Phase 3 results for nasal drug depemokimab
GSK's Depemokimab Shows Positive Trial Results, Boosting Stock
GSK's Depemokimab Shows Positive Trial Results, Boosting Stock
Stocks to Watch Monday: Tesla, Boeing, MicroStrategy, GSK
Who will attend the UK investment summit and what is on the agenda?
Guests at all-day event include the NHS boss, execs from Google, BlackRock and Aviva – and Gareth Southgate ‘I’ve faced a lot of challenges’: Poppy Gustafsson on her new role The government will host ...
Doubts on UK Industrial Strategy Cloud Investment Push at Summit
When UK Prime Minister Keir Starmer welcomes business leaders to a major investment summit in London on Monday, his message to executives from the likes of BlackRock, Vodafone and GSK will be simple: ...
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
Earlier this week, GSK plc (NYSE: GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability cases in the U.S. state courts . These cases account for ...
MARKET REPORT: GSK shares jump as Zantac cancer claims deal reached
Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and several rivals into crisis.
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
In June, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccine...
GSK: The Worst Is Finally Over (Rating Upgrade)
GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable at 12.4x. Explore more details here.